The Knowledge Hub for Medical Imaging Professionals: Transforming Radiology with Structured Reporting, Data-Driven Approaches and Multicentric Research

Access breakthrough research, innovative case studies and collaborative projects advancing radiology worldwide. Dive into our activities and product updates, and learn who we are as a company and as a team.

Interview with Prof. Timm Denecke about the RACOON-MARDER project and AI-powered early detection of liver cancer using MRI

Rethinking Early Detection: How RACOON-MARDER Aims to Spot Liver Cancer Sooner

Hepatocellular carcinoma (HCC) is often diagnosed too late, limiting treatment options and survival. The RACOON-MARDER project aims to change that. By combining MRI imaging, clinical data, and AI-based risk stratification, researchers hope to identify high-risk patients earlier and enable personalized, intensified surveillance beyond what traditional ultrasound can offer.

In this interview, Prof. Dr. Timm Denecke (University Hospital Leipzig) explains how AI can make the invisible visible - and why the RACOON infrastructure is key to advancing liver cancer research.

Read more here.

Related Resources

Related Resources

AI lung nodules detection in contextflow and Lung-RADS in mint Lesion

Leverage Advanced AI-Driven Nodule Detection and Analysis for Comprehensive Patient Care

Discover the power of streamlined AI-driven lung screening with contextflow ADVANCE Chest CT integrated into mint Lesion. With automated lung nodule…

Hands holding a glass lung to evoke image of lung cancer

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…

Image shows graphic related to study's research on iRECIST and RECIST

University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…